Carnipure Reduces Free Fatty Acid Levels in Pregnancy

BASEL, SwitzerlandSupplementation with 2 g/d L-carnitine in the form of Carnipure tartrate (from Lonza) during pregnancy can significantly reduce the increase of plasma free fatty acid levels frequently observed during pregnancy (Am J Obstet Gynecol 2010;4:49). Increased levels of plasma free fatty acids are thought to be the main cause of insulin resistance, a major factor in developing gestational diabetes.

As early as the 12th week of pregnancy and up to delivery, plasma total and free L-Carnitine levels drop significantly. Low free L-Carnitine levels have been shown to result in a two- to three-fold down regulation of the expression of carnitine acyltransferases, the enzymes involved in fatty acid oxidation in the mitochondria. When the relative mRNA levels of these enzymes are low, the plasma levels of free fatty acids increase. Supplementation with Carnipure tartrate resulted in a significant increase of the expression of these enzymes, thus resulting in significantly decreased levels of plasma free fatty acids. Additionally, the plasma levels of L-Carnitine were found to be higher after supplementation.

Carnipure tartrate has clear benefits for pregnant women. It not only maintains normal L-Carnitine levels, but also decreases plasma free fatty acids, thus potentially decreasing the risk for developing insulin resistance," commented Prof. Dr. Alfred Lohninger, lead author of the study.

A nutrient produced in the body and found in some dietary sources, L-Carnitine plays a critical role in fat and energy metabolism.  It shuttles long-chain fatty acids into the cells mitochondria where they are broken down for energy generation.

Carnipure can be integrated into dietary supplements as well as functional foods and beverages.

Lonza supplies the pharmaceutical, healthcare and life science industries. Its products and services span from research to final product manufacture. Lonza produces and supports active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products.